“The use of outside experts for reviewing patents could prevent the granting of unmerited patents and high drug prices in many developing countries. This is the view of Tahir Amin, co-Director of the Initiative for Medicines, Access & Knowledge (I-MAK), which helped prepare a pre-grant patent opposition to Gilead’s AIDS treatment, Viread (tenofovir disoproxil fumarate), on behalf of Indian patient groups. Read more.